MarketCap
BioCryst Pharmaceuticals BCRX
$ 9.82
0.41%
Facebook
X
Telegram
BioCryst Pharmaceuticals Financial Ratios 2025-2008 | BCRX
Brief overview of BioCryst Pharmaceuticals's market valuation
This overview follows the five latest available observations from 2021 through 2025.
The current valuation set is P/S 2.57x (median 3.81x), P/B 3.06x (median 5.39x). On average, this basket is 37.9% below its own five-year medians. The market values the business at a discount to recent history.
End-period return metrics are ROE -2.2%, ROA 51.3%, ROCE -2.9%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
On PEG (0.72x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The cash cycle lengthened by 491.2 days to -95 days. Operations require more funding.
What the ratios show
BioCryst Pharmaceuticals's restrained price comes with modest current quality. Better efficiency is needed for revaluation.
Annual Financial Ratios BioCryst Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
8.5 | -19.3 | -5.0 | -6.8 | -16.2 | -9.9 | -3.0 | -8.9 | -5.9 | -8.1 | -11.8 | -15.0 | -19.0 | -2.0 | -2.8 | -9.0 | - | - |
P/S |
2.6 | 3.8 | 3.4 | 6.2 | 18.9 | 101.2 | 6.6 | 43.5 | 15.3 | 16.9 | 10.5 | 50.0 | 33.0 | 3.0 | 8.0 | 4.9 | - | - |
EPS |
1.3 | -0.4 | -1.2 | -1.3 | -1.0 | -1.1 | -940 | -1.0 | -0.8 | -0.8 | -0.6 | -0.7 | -0.6 | -0.8 | -1.3 | -0.8 | -0.3 | - |
EV (Enterprise Value) |
2.8 B | 2.58 B | 1.99 B | 1.38 B | 2.47 B | 1.53 B | 347 M | 970 M | 429 M | 511 M | 556 M | 686 M | 601 M | 115 M | 209 M | 291 M | -41.1 M | -22.3 M |
EBITDA per Share |
1.63 | -0.01 | -0.53 | -0.79 | -0.99 | -1.04 | -0.854 | -0.906 | -0.671 | -0.653 | -0.539 | -0.683 | -0.551 | -0.637 | -1.08 | -0.71 | - | - |
EV/EBITDA |
8.2 | -1988.7 | -19.5 | -9.4 | -13.8 | -8.2 | -2.9 | -10.0 | -6.8 | -9.9 | -13.0 | -14.4 | -19.1 | -2.8 | -3.5 | -9.1 | 3.0 | - |
PEG |
-0.0 | 0.72 | 0.59 | -1.31 | -1.65 | -0.66 | -0.73 | 0.35 | 1.46 | 0.3 | -0.89 | 0.64 | -0.63 | -0.05 | 0.04 | - | - | - |
P/B |
-18.9 | -3.6 | -2.5 | 3.1 | 5.1 | 5.4 | 8.5 | 18.3 | 4.6 | 282.1 | 10.6 | 9.0 | -508.5 | -172.2 | 10.7 | 2.8 | - | - |
P/CF |
6.5 | -33.0 | -11.8 | -10.4 | -20.9 | -13.3 | -3.6 | -9.7 | -9.3 | -7.6 | -27.9 | -17.6 | -21.6 | -2.1 | -4.9 | -10.7 | - | - |
ROE % |
-221.45 | 18.68 | 49.73 | 83.88 | 172.04 | 949.09 | -284.68 | -205.65 | -78.53 | -3494.55 | -90.14 | -59.75 | 2673.89 | 8608.15 | -384.63 | -51.68 | -15.59 | - |
ROA % |
51.32 | -18.12 | -43.82 | -44.93 | -31.30 | -54.62 | -62.13 | -68.95 | -36.90 | -61.38 | -34.54 | -33.02 | -61.61 | -68.04 | -69.27 | -30.93 | - | - |
ROCE % |
-286.18 | 0.53 | 22.77 | 50.39 | 166.12 | 907.26 | -119.90 | -121.79 | -55.51 | -136.97 | -65.63 | -57.80 | -91.39 | -79.89 | -88.69 | -52.45 | -15.92 | - |
Current Ratio |
0.8 | 0.5 | 0.5 | - | - | - | 1.8 | 1.6 | 1.7 | 1.2 | 1.0 | 1.5 | 2.8 | 2.4 | 2.0 | - | - | - |
DSO |
38.8 | 32.9 | 5.8 | 6.9 | 11.9 | 311.4 | 165.5 | 75.9 | 88.6 | 121.4 | 47.2 | 254.5 | 44.5 | 63.3 | 140.7 | 88.4 | - | - |
DIO |
129.0 | 546.9 | 2289.5 | 1233.9 | 576.4 | 828.8 | - | 1277.9 | - | 67.6 | 310.3 | 2043.4 | - | - | - | 1905.6 | - | - |
DPO |
262.8 | 484.0 | 1435.6 | 1200.8 | 1174.4 | 3850.3 | 1245.0 | 6020.6 | 1359.0 | 577.3 | 1791.7 | 8523.6 | 15546.0 | 10988.7 | - | 17403.3 | - | - |
Operating Cycle |
167.8 | 579.9 | 2295.4 | 1240.8 | 588.2 | 1140.2 | 165.5 | 1353.8 | 88.6 | 189.1 | 357.5 | 2297.9 | 44.5 | 63.3 | - | 1994.1 | - | - |
Cash Conversion Cycle |
-95.0 | 95.9 | 859.8 | 39.9 | -586.2 | -2710.1 | -1079.4 | -4666.8 | -1270.3 | -388.3 | -1434.1 | -6225.7 | -15501.5 | -10925.4 | - | -15409.2 | - | - |
All numbers in USD currency
Quarterly Financial Ratios BioCryst Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.31 | -2.98 | 0.06 | 0.02 | - | - | -0.07 | -0.06 | -0.17 | - | -0.19 | -0.4 | -0.28 | - | -0.23 | -0.32 | -0.4 | - | -0.33 | -240 | -0.36 | -0.34 | -260 | -240 | -0.24 | -0.02 | -0.34 | -0.34 | -0.28 | -0.25 | -0.28 | -0.19 | -0.26 | -0.2 | -0.18 | -0.21 | -0.19 | -0.06 | -0.16 | -0.22 | -0.31 | -0.25 | -0.2 | 0.07 | -0.21 | -0.16 | -0.12 | -0.23 | -0.17 | -0.09 | -0.14 | -0.23 | -0.09 | -0.22 | -0.19 | -0.25 | -0.13 | -0.29 | -0.32 | -0.36 | -0.29 |
EBITDA per Share |
0.39 | -2.89 | - | - | 0.1 | - | - | - | -0.07 | - | - | - | -0.15 | - | -0.09 | -0.19 | -0.27 | - | -0.25 | -0.17 | -0.29 | - | -0.24 | -0.22 | -0.23 | - | -0.22 | -0.22 | -0.19 | - | -0.25 | -0.16 | -0.2 | - | -0.13 | -0.15 | -0.11 | - | -0.12 | -0.16 | -0.26 | - | -0.18 | 0.07 | -0.2 | - | -0.16 | -0.18 | -0.12 | - | -0.11 | -0.2 | -0.09 | - | -0.15 | -0.19 | -0.09 | - | -0.27 | -0.3 | -0.25 |
ROE % |
108.54 | 125.79 | -1.54 | 4.45 | 13.08 | 13.09 | 21.89 | 38.27 | 51.85 | 44.42 | 61.94 | 80.75 | 106.55 | 90.31 | 130.30 | 153.50 | 211.62 | 166.44 | 480.49 | 679.91 | 839.62 | 949.09 | 628.18 | 290.50 | -8.30 | -284.68 | -333.55 | -295.38 | -234.48 | -205.65 | -173.26 | -131.22 | -113.91 | -78.53 | -340.56 | -1053.04 | -2064.63 | -3494.55 | -3247.19 | -2547.28 | -1505.26 | -90.14 | -67.57 | -48.48 | -78.12 | -59.75 | 437.84 | 1159.95 | 2260.31 | 2673.89 | 4626.32 | 6052.32 | 7675.29 | 8608.15 | 6084.47 | 3850.25 | 1036.39 | -384.63 | -97.66 | -109.89 | -87.98 |
ROA % |
-137.16 | -151.20 | 1.15 | -4.42 | -13.09 | -13.10 | -20.01 | -31.37 | -39.15 | -31.59 | -39.20 | -46.35 | -54.26 | -43.80 | -59.38 | -51.76 | -74.36 | -60.31 | -78.38 | -70.03 | -65.99 | -54.62 | -38.04 | -45.71 | -55.64 | -62.13 | -79.31 | -78.02 | -69.12 | -68.95 | -61.24 | -49.57 | -46.48 | -36.90 | -30.95 | -35.29 | -43.94 | -61.38 | -71.18 | -70.30 | -48.18 | -35.16 | -28.86 | -23.29 | -38.00 | -33.02 | -35.60 | -45.59 | -59.80 | -61.61 | -69.75 | -70.26 | -66.72 | -68.04 | -64.84 | -65.54 | -63.96 | -69.27 | -17.59 | -19.79 | -15.85 |
ROCE % |
90.31 | 107.29 | -21.03 | -15.25 | -5.14 | -0.44 | 2.46 | 9.43 | 19.92 | 16.88 | 24.07 | 37.45 | 62.55 | 53.89 | 84.21 | 104.91 | 157.14 | 126.72 | 349.25 | 518.86 | 703.71 | 635.20 | 543.44 | 229.63 | -46.97 | -259.71 | -317.59 | -262.90 | -216.73 | -140.06 | -155.99 | -116.65 | -92.33 | -47.21 | -632.83 | -1385.59 | -2574.16 | -2561.41 | -2588.99 | -1992.18 | -1253.72 | -46.62 | -61.97 | -49.75 | -70.71 | -40.48 | 574.53 | 1668.21 | 2155.69 | 2165.45 | 3931.09 | 5557.49 | 5580.70 | 5108.59 | 5022.11 | 3160.27 | 841.19 | -260.35 | -86.49 | -96.20 | -77.66 |
Current Ratio |
0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | - | - | 0.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
46.0 | 58.5 | 52.2 | 51.5 | 54.1 | - | 1.2 | 2.4 | 2.9 | - | 2.0 | 1.8 | 6.2 | - | 1.8 | 1.4 | 3.6 | - | 10.9 | 13.7 | 40.1 | 187.3 | 123.3 | 262.0 | 287.5 | 50.9 | 1138.5 | 1395.6 | 204.9 | 143.6 | 269.4 | 31.4 | 119.5 | 143.5 | 63.7 | 180.1 | 72.0 | 89.1 | 103.1 | 167.1 | 142.1 | 123.8 | 51.9 | 22.0 | 67.5 | 64.5 | 108.5 | 239.6 | 78.7 | 19.4 | 85.6 | 235.1 | 85.7 | 101.5 | 72.3 | 98.9 | 38.8 | 101.8 | 101.4 | 142.5 | - |
DIO |
143.1 | 95.2 | 214.4 | 194.3 | 149.4 | - | 170.7 | 919.2 | 2108.6 | - | 2352.4 | 2781.3 | 2695.3 | - | 347.9 | 2994.2 | 6173.9 | - | 1814.9 | 2298.0 | 93.6 | - | 423.4 | - | - | - | - | - | 73.3 | - | - | - | - | - | 52.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
266.4 | 140.2 | 295.3 | 303.9 | 216.7 | - | 302.2 | 528.9 | 1183.1 | - | 1015.3 | 1028.0 | 1010.0 | - | 111.0 | 2574.5 | 8059.6 | - | 2299.0 | 3627.9 | 248.4 | - | 1125.6 | - | - | - | - | - | 709.5 | - | - | - | - | - | 506.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 266.6 | 245.9 | 203.5 | - | 171.9 | 921.6 | 2111.5 | - | 2354.3 | 2783.1 | 2701.5 | - | 349.8 | 2995.5 | 6177.4 | - | 1825.8 | 2311.7 | 133.7 | 187.3 | 546.7 | 262.0 | 287.5 | 50.9 | 1138.5 | 1395.6 | 278.3 | 143.6 | 269.4 | 31.4 | 119.5 | 143.5 | 115.9 | 180.1 | 72.0 | 89.1 | 103.1 | 167.1 | 142.1 | 123.8 | 51.9 | 22.0 | 67.5 | 64.5 | 108.5 | 239.6 | 78.7 | 19.4 | 85.6 | 235.1 | 85.7 | 101.5 | 72.3 | 98.9 | 38.8 | 101.8 | 101.4 | 142.5 | - |
Cash Conversion Cycle |
- | - | -28.7 | -58.0 | -13.2 | - | -130.3 | 392.7 | 928.4 | - | 1339.0 | 1755.1 | 1691.5 | - | 238.7 | 421.1 | -1882.1 | - | -473.2 | -1316.2 | -114.7 | 187.3 | -578.9 | 262.0 | 287.5 | 50.9 | 1138.5 | 1395.6 | -431.3 | 143.6 | 269.4 | 31.4 | 119.5 | 143.5 | -390.5 | 180.1 | 72.0 | 89.1 | 103.1 | 167.1 | 142.1 | 123.8 | 51.9 | 22.0 | 67.5 | 64.5 | 108.5 | 239.6 | 78.7 | 19.4 | 85.6 | 235.1 | 85.7 | 101.5 | 72.3 | 98.9 | 38.8 | 101.8 | 101.4 | 142.5 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company BioCryst Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
